Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Japan Hospice Holdings Inc. (7061:JPX), powered by AI.
Japan Hospice Holdings Inc. is currently trading at ¥556. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Japan Hospice Holdings Inc. on Alpha Lenz.
View Japan Hospice Holdings Inc.'s valuation metrics on Alpha Lenz.
“Japan Hospice Holdings Inc.'s ROE is 7.8%. Explore profitability and growth together.”
Ask for details →Japan Hospice Holdings Inc. is a prominent player in the healthcare sector, primarily operating within the palliative care industry. The company is focused on providing specialized hospice services aimed at improving the quality of life for patients with terminal illnesses. Their services encompass pain management, psychological support, and comprehensive end-of-life care tailored to the needs of patients and their families. Japan Hospice Holdings' operations are significant given the aging population in Japan, where demand for such compassionate and professional care is increasingly becoming essential. The company's activities contribute to the healthcare infrastructure by alleviating the burden on hospitals and ensuring dignity and comfort for patients in their final stages of life. By operating across various facilities in Japan, Japan Hospice Holdings plays a crucial role in redefining end-of-life care, emphasizing the importance of specialized care environments that prioritize patient well-being and emotional support. As the need for hospice care continues to grow, the company stands as a pivotal entity within Japan's broader healthcare landscape, reflecting its commitment to high standards of care and service excellence.
“Japan Hospice Holdings Inc.'s ROE is 7.8%. Explore profitability and growth together.”
Ask for details →Japan Hospice Holdings Inc. (ticker: 7061) is a company listed on JPX in the Healthcare sector (Medical Care Facilities). It has approximately 1,094 employees.
The current price is 556 with a P/E ratio of -x and P/B of -x.
ROE is 7.80% and operating margin is 5.99%. Annual revenue is $14.2B.